ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1108

Effect of Body Mass Index on Serum Urate and Renal Uric Acid Handling Responses to an Oral Inosine Load

Nicola Dalbeth1, Jordyn de Kwant1, Gregory Gamble2, Amanda Phipps-Green3, Anne Horne2, Lisa K. Stamp4 and Tony R. Merriman5, 1University of Auckland, Auckland, New Zealand, 2Department of Medicine, University of Auckland, Auckland, New Zealand, 3University of Otago, Dunedin, New Zealand, 4University of Otago, Christchurch, New Zealand, 5Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: gout, Kidney, obesity and uric acid

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Session Title: Metabolic and Crystal Arthropathies Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Increased body mass index (BMI) is an important risk factor for hyperuricemia and gout. It is unknown whether overweight and obesity influences serum urate primarily through increased urate production or reduced renal clearance of uric acid. Inosine is a purine nucleoside that functions as an intermediate in the purine salvage and degradation pathways. Oral administration of inosine allows analysis of the effects of a standardized purine load on both serum urate concentrations and renal uric acid handling. The aim of this study was to determine the influence of body mass index on the response to an inosine load.

Methods: Following an overnight fast, 100 healthy participants, recruited by public advertising, attended a study visit. Exclusion criteria included chronic kidney disease stage 3 or worse, gout, diabetes mellitus and diuretic use. Blood and urine samples were obtained for urate and creatinine, prior to and then 15, 30, 60, 120, and 180 minutes after a single oral 1.5g dose of inosine. Clinical features including age, sex, ethnicity and BMI were recorded. Data were analysed according to increased BMI (25kg/m2 or more) and low/normal BMI (less than 25kg/m2). The primary endpoint was change in serum urate and secondary endpoint was change in fractional excretion of uric acid (FEUA). Data were analysed using a mixed models approach to repeated measures.

Results : In the entire study population, oral intake of inosine led to large increases in serum urate (mean increase 1.6mg/dL) and FEUA (mean increase 3.7%) over the 180 minute study period (P<0.0001 for both). Although participants in the increased BMI group (n=52) had higher serum urate concentrations at baseline (age, sex, ethnicity-adjusted P=0.002), this group had a smaller increase in serum urate following the inosine load (age, sex, ethnicity-adjusted ANCOVA P=0.0035, Figure 1A). The two BMI groups had a similar FEUA at baseline (age, sex, ethnicity-adjusted P=0.98), but those in the increased BMI group had a smaller increase in FEUA following the inosine load (age, sex, ethnicity-adjusted ANCOVA P=0.0003, Figure 1B). 

Conclusion:  People with increased BMI do not have an exaggerated hyperuricemic response to a standardized purine load. However, those with increased BMI do have reduced renal excretion of uric acid following inosine loading. These data demonstrate impaired renal clearance of uric acid following dietary purine intake in those with overweight and obesity.

 

Figure 1. A Change in serum urate, and B. Change in FEUA following an oral inosine load in different BMI groups. Data are presented as unadjusted mean (95% CI). Age, sex and ethnicity-adjusted ANCOVA P values are shown.

 


Disclosure: N. Dalbeth, Takeda, AstraZeneca, Abbvie, 9; J. de Kwant, None; G. Gamble, None; A. Phipps-Green, None; A. Horne, None; L. K. Stamp, Amgen, 8; T. R. Merriman, Ardea Biosciences, 2.

To cite this abstract in AMA style:

Dalbeth N, de Kwant J, Gamble G, Phipps-Green A, Horne A, Stamp LK, Merriman TR. Effect of Body Mass Index on Serum Urate and Renal Uric Acid Handling Responses to an Oral Inosine Load [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/effect-of-body-mass-index-on-serum-urate-and-renal-uric-acid-handling-responses-to-an-oral-inosine-load/. Accessed March 21, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-body-mass-index-on-serum-urate-and-renal-uric-acid-handling-responses-to-an-oral-inosine-load/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences